Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
Wearing masks at home can limit spread: Study
06:08pm, Thursday, 28'th May 2020
Close daily contact, such as eating meals at a table or watching TV together raised chances of others getting infected 18-fold while diarrhoea as a symptom in patient zero quadrupled infection risk, s
Eagle Pharmaceuticals to Present at June Investor Conferences
08:30pm, Tuesday, 26'th May 2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcomin
Eagle Pharmaceuticals to Present at June Investor Conferences
12:00am, Tuesday, 26'th May 2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Ch
Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
08:05pm, Friday, 22'nd May 2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from fed
TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results
12:00am, Wednesday, 20'th May 2020
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary
Hudson Executive Capital LP Buys Tivity Health Inc, ViewRay Inc, Sells Eagle Pharmaceuticals Inc
12:00am, Tuesday, 19'th May 2020
This week in Other Barks & Bites: the Supreme Court finds that Lucky Brand Dungarees isn’t precluded from asserting new defenses under federal preclusion principles; the Federal Circuit issues decis
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Just Slashed This Year's Estimates
03:50pm, Thursday, 14'th May 2020
Market forces rained on the parade of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shareholders today, when the analysts...
CASI Pharmaceuticals: 2-Year Price Lows Make For Intriguing Risk-On Buy
02:27am, Wednesday, 13'th May 2020
CASI is focused on developing and commercialising drugs for the Chinese market most notably within the field of hematology/oncology using an innovative in-licen
AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data at the ASCO20 Virtual Scientific Program
12:00am, Wednesday, 13'th May 2020
AstraZeneca will present ground-breaking new results across its broad portfolio of cancer medicines during the 2020 American Society of Clinical Oncol
Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
08:30pm, Tuesday, 12'th May 2020
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat a
U.S. RESEARCH ROUNDUP-Digital Realty Trust, Pilgrims Pride, Terraform Power
07:26am, Tuesday, 12'th May 2020
Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Digital Realty Trust, Pilgrims Pride and Terraform Power,
on Tuesday.
HIGH
Tyme Technologies to Webcast Conference Call of Fourth Quarter and Fiscal Year 2020 Financial and Operating Results on May 20, 2020
12:00am, Tuesday, 12'th May 2020
Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the Com
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2020 Results - Earnings Call Transcript
06:09pm, Monday, 11'th May 2020
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q1 2020 Results Earnings Conference Call May 11, 2020, 08:30 AM ET Company Participants Lisa Wilson - Investor Relatio
